IGF-1R

Phase II SARC-022 IGF-1R Trial Currently Recruiting and Planning to Add New Sites

The Sarcoma Alliance for Research through Collaboration (SARC) in partnership with the National Cancer Institute (NCI) is currently recruiting patients for its Phase II trial (SARC-022) of Linsitinib (OSI-906), an IGF-1R inhibitor. Linsitinib is targeted [...]

By |2019-09-20T13:23:36-04:00January 14th, 2013|Clinical Trials, News|
Go to Top